- Home
- GLPG vs DV Comparison
GLPG vs DV Comparison
Compare GLPG & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- DV
- Stock Information
- Founded
- GLPG 1999
- DV 2008
- Country
- GLPG Belgium
- DV United States
- Employees
- GLPG N/A
- DV N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- DV Computer Software: Prepackaged Software
- Sector
- GLPG Health Care
- DV Technology
- Exchange
- GLPG Nasdaq
- DV Nasdaq
- Market Cap
- GLPG 2.1B
- DV 1.9B
- IPO Year
- GLPG 2005
- DV 2021
- Fundamental
- Price
- GLPG $30.42
- DV $10.29
- Analyst Decision
- GLPG Hold
- DV Buy
- Analyst Count
- GLPG 4
- DV 17
- Target Price
- GLPG $31.33
- DV $16.56
- AVG Volume (30 Days)
- GLPG 169.3K
- DV 3.8M
- Earning Date
- GLPG 11-05-2025
- DV 11-07-2025
- Dividend Yield
- GLPG N/A
- DV N/A
- EPS Growth
- GLPG N/A
- DV N/A
- EPS
- GLPG N/A
- DV 0.26
- Revenue
- GLPG $336,643,201.00
- DV $733,324,000.00
- Revenue This Year
- GLPG $1.77
- DV $18.45
- Revenue Next Year
- GLPG $0.44
- DV $11.70
- P/E Ratio
- GLPG N/A
- DV $39.16
- Revenue Growth
- GLPG 10.31
- DV 14.86
- 52 Week Low
- GLPG $22.36
- DV $7.64
- 52 Week High
- GLPG $37.78
- DV $23.11
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- DV 38.94
- Support Level
- GLPG $30.17
- DV $10.19
- Resistance Level
- GLPG $33.12
- DV $10.50
- Average True Range (ATR)
- GLPG 0.75
- DV 0.49
- MACD
- GLPG -0.04
- DV -0.01
- Stochastic Oscillator
- GLPG 22.55
- DV 69.44
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.